{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:09:29Z","timestamp":1790809769620,"version":"4.1.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Healthcare workers exposure to antineoplastic drugs can lead to adverse health effects. Guidelines promote the safe handling of antineoplastic drugs, but no safe exposure limit was determined. Regular surface sampling contributes to ensuring workers safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cross-sectional monitoring is conducted once a year with voluntary Canadian centers, since 2010. Twelve standardized sampling sites were sampled. Samples were analyzed by high performance mass coupled liquid chromatography. The limits of detection (in ng\/cm\n                      <jats:sup>2<\/jats:sup>\n                      ) were: 0.001 for cyclophosphamide and gemcitabine; 0.3 for docetaxel and ifosfamide; 0.04 for 5-fluorouracil and paclitaxel; 0.003 for irinotecan; 0.002 for methotrexate; 0.01 for vinorelbine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The surfaces from 109 centers were sampled between 01\/01\/2020\u201318\/06\/2020. Twenty-six centers delayed their participation because of the COVID-19 pandemic. 1217 samples were analyzed. Surfaces were frequently contaminated with cyclophosphamide (34% positive, 75th percentile 0.00165\u2009ng\/cm\n                      <jats:sup>2<\/jats:sup>\n                      ) and gemcitabine (16% and &lt;0.001\u2009ng\/cm\n                      <jats:sup>2<\/jats:sup>\n                      ). The armrest of patient treatment chairs (84% to at least one drug), the front grille inside the biological safety cabinet (BSC) (73%) and the floor in front of the BSC (55%) were frequently contaminated. Centers that prepared \u22655000 antineoplastic drugs annually had higher concentration of cyclophosphamide on their surfaces (p\u2009&lt;\u20090.0001). Contamination measured on the surfaces was reduced from 2010 to 2020.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This large-scale study showed reproducible long term follow up of the contamination of standardized sites of Canadian centers and a reduction in surface contamination from 2010 to 2020. Periodic surface sampling help centers meet their continuous improvements goals to reduce exposure as much as possible. The COVID-19 pandemic had a limited impact on the program.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155221992103","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T06:36:22Z","timestamp":1613198182000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-8339","authenticated-orcid":false,"given":"Claire","family":"Chabut","sequence":"first","affiliation":[{"name":"Pharmacy Practice Research Unit, Pharmacy Department, CHU Sainte-Justine, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Tanguay","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Research Unit, Pharmacy Department, CHU Sainte-Justine, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gagn\u00e9","sequence":"additional","affiliation":[{"name":"Centre de Toxicologie du Qu\u00e9bec, Institut national de sant\u00e9 publique du Qu\u00e9bec, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Caron","sequence":"additional","affiliation":[{"name":"Centre de Toxicologie du Qu\u00e9bec, Institut national de sant\u00e9 publique du Qu\u00e9bec, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-4967","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Bussi\u00e8res","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Research Unit, Pharmacy Department, CHU Sainte-Justine, Montreal, Canada"},{"name":"Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"bibr1-1078155221992103","volume-title":"Cancer incidence in five continents","author":"Ferlay J","year":"2014"},{"key":"bibr2-1078155221992103","unstructured":"Cancer Care Ontario. Recommendations for the safe use and handling of oral anti-cancer drugs (OACDs) in community pharmacy: a Pan-Canadian consensus guideline, www.cancercareontario.ca\/en\/content\/recommendations-safe-use-and-handling-oral-anti-cancer-drugs-oacds-community-pharmacy-pan-canadian-consensus-guideline (2017, accessed 8 January 2021)."},{"key":"bibr3-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1191\/1078155205jp155oa"},{"key":"bibr4-1078155221992103","volume":"17","author":"Gianfredi V","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"bibr5-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2017.08.002"},{"key":"bibr6-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2016.05.001"},{"key":"bibr7-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01616"},{"key":"bibr8-1078155221992103","unstructured":"Gallant C, Bussi\u00e8res J-F, Auger Deniseet\u00a0al. Guide de pr\u00e9vention. Manipulation s\u00e9curitaire des m\u00e9dicaments dangereux.\n                      ASSTSAS\n                      , www.asstsas.qc.ca (2008, accessed 8 January 2021)."},{"key":"bibr9-1078155221992103","first-page":"1","volume":"13","author":"International Society of Oncology Pharmacy Practicioners Standards Committee","year":"2007","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"bibr10-1078155221992103","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp180564"},{"key":"bibr11-1078155221992103","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"bibr12-1078155221992103","unstructured":"National Institute for Occupational Safety and Health. NIOSH alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, www.cdc.gov\/niosh\/docs\/2004-165\/pdfs\/2004-165.pdf (2004, accessed 8 January 2021)."},{"key":"bibr13-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1080\/15459624.2016.1165912"},{"key":"bibr14-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1080\/15459624.2020.1776299"},{"key":"bibr15-1078155221992103","unstructured":"Labr\u00e8che F, Ouellet C, Roberge B, et\u00a0al. Antin\u00e9oplasiques en milieu hospitalier \u00c9tude pilote sur l\u2019exposition potentielle du personnel d\u2019hygi\u00e8ne et de salubrit\u00e9, www.deslibris.ca\/ID\/10103819 (2020, accessed 16 November 2020)."},{"key":"bibr16-1078155221992103","first-page":"761","volume":"58","author":"Hon C-Y","year":"2014","journal-title":"Ann Occup Hyg"},{"key":"bibr17-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219868525"},{"key":"bibr18-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219850305"},{"key":"bibr19-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216679027"},{"key":"bibr20-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1188\/19.ONF.689-700"},{"key":"bibr21-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1188\/20.ONF.263-272"},{"key":"bibr22-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2018.05.002"},{"key":"bibr23-1078155221992103","first-page":"E86","volume":"46","author":"Lin Y","year":"2019","journal-title":"Oncol Nurs Forum"},{"key":"bibr24-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220907129"},{"key":"bibr25-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1080\/15459624.2016.1237026"},{"key":"bibr26-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217704990"},{"key":"bibr27-1078155221992103","first-page":"57","volume-title":"Fate and effects of anticancer drugs in the environment","author":"Blahova L"},{"key":"bibr28-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2010.04.030"},{"key":"bibr29-1078155221992103","first-page":"589","volume":"69","author":"Dugheri S","year":"2018","journal-title":"Med Pr"},{"key":"bibr30-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220907125"},{"key":"bibr31-1078155221992103","unstructured":"Commission Directive 2009\/90\/EC of 31 July 2009 laying down, pursuant to Directive 2000\/60\/EC of the European Parliament and of the Council, technical specifications for chemical analysis and monitoring of water statusText with EEA relevance."},{"key":"bibr32-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1080\/1047322X.1990.10389587"},{"key":"bibr33-1078155221992103","unstructured":"Kiffmeyer TK, Tuerk J, Hahn M, et al. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies \u2013 the MEWIP project.\n                      Ann Occup Hyg\n                      2013; 57(4): 444\u201355."},{"key":"bibr34-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz033"},{"key":"bibr35-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.8594"},{"key":"bibr36-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1093\/annweh\/wxx070"},{"key":"bibr37-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1021\/es304976q"},{"key":"bibr38-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1097\/OP9.0000000000000024"},{"key":"bibr39-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219831427"},{"key":"bibr40-1078155221992103","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219865931"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155221992103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155221992103","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155221992103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:10Z","timestamp":1777688770000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155221992103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/1078155221992103"],"URL":"https:\/\/doi.org\/10.1177\/1078155221992103","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]}}}